Management's Discussion and Analysis of Financial Condition and Results of
Operations ("MD&A") is designed to provide a reader of our Unaudited Condensed
Consolidated Financial Statements and Notes thereto that are contained in this
quarterly report, with a narrative from the perspective of management. You
should also consider this information with the information included in our
Annual Report on Form 10-K for the year ended June 30, 2021, and our other
filings with the SEC, including our quarterly and current reports that we have
filed since June 30, 2021 through the date of this report. In the following
MD&A, we have rounded many numbers to the nearest one thousand dollars. These
numbers should be read as approximate. All inter-company transactions have been
eliminated. Our fiscal year ends on June 30. For example, reference to fiscal
year 2022 refers to the year ending June 30, 2022. This report covers the three
and six months ended December 31, 2021. Results of operations for the three and
six months ended December 31, 2021 are not necessarily indicative of the results
that may be achieved for the full fiscal year ending June 30, 2022.
Overview
Dynatronics is a leading medical device company committed to providing
high-quality restorative products designed to accelerate achieving optimal
health. The Company designs, manufactures, and sells a broad range of products
for clinical use in physical therapy, rehabilitation, pain management, and
athletic training. Through its distribution channels, Dynatronics markets and
sells to orthopedists, physical therapists, chiropractors, athletic trainers,
sports medicine practitioners, clinics, hospitals, and consumers. The Company's
products are marketed under a portfolio of high-quality, well-known industry
brands including Bird & Cronin®, Solaris™, Hausmann®, Physician's Choice®, and
PROTEAM™, among others. More information is available at www.dynatronics.com.
Results of Operations
Net Sales
Net sales decreased $1,438,000, or 12.0%, to $10,530,000 for the quarter ended
December 31, 2021, compared to net sales of $11,968,000 for the quarter ended
December 31, 2020. Net sales decreased $1,270,000, or 5.3%, to $22,831,000 for
the six months ended December 31, 2021, compared to net sales of $24,101,000 for
the six months ended December 31, 2020. The year-over-year decrease is primarily
due to a reduction in sales of third-party distributed products which have been
discontinued. This was partially offset by an increase in customer demand
compared to the prior year period in which we experienced the impact of COVID-19
precautions and associated deferral on elective procedures which reduced demand
for our products.
11
Table of Contents
Gross Profit
Gross profit for the quarter ended December 31, 2021 decreased $1,260,000, or
about 37.7%, to $2,081,000, or 19.8% of net sales. By comparison, gross profit
for the quarter ended December 31, 2020 was $3,341,000, or 27.9% of net sales.
Gross profit for the six months ended December 31, 2021 decreased $1,498,000, or
about 20.7%, to $5,745,000, or 25.2% of net sales. By comparison, gross profit
for the six months ended December 31, 2020 was $7,243,000, or 30.1% of net
sales. The year-over-year decrease in gross profit was primarily attributable to
higher freight and raw material costs due to the impact of COVID-19 on the
global supply chain, higher personnel costs, and changes to product mix. These
items were partially offset by the benefit of the employee retention credit
under the CARES Act, as amended, of $97,000 in the quarter ended September 30,
2021.
Selling, General and Administrative Expenses
Selling, general and administrative ("SG&A") expenses decreased $456,000, or
11.6%, to $3,482,000 for the quarter ended December 31, 2021, compared to
$3,938,000 for the quarter ended December 31, 2020. Selling expenses decreased
$261,000 compared to the prior year period, due primarily to lower commission
expense and salaries for rehabilitation products sales force, partially offset
by higher marketing salaries. General and administrative ("G&A") expenses
decreased $198,000 compared to the prior-year period. The decrease in SG&A was
driven primarily by the elimination of distributed products and our direct sales
channel which has reduced complexity and associated support costs.
SG&A expenses decreased $605,000, or 7.4%, to $7,578,000 for the six months
ended December 31, 2021, compared to $8,183,000 for the six months ended
December 31, 2020. Selling expenses decreased $268,000 compared to the prior
year period, due primarily to lower commission expense and salaries for
rehabilitation products sales force, partially offset by higher marketing
salaries. G&A expenses decreased $340,000 compared to the prior-year period. The
decrease in SG&A was driven primarily by the elimination of distributed products
and our direct sales channel which has reduced complexity and associated support
costs.
Net Other Income (Expense)
Net other expense for the quarter ended December 31, 2021, was $40,000 compared
to net other expense of $66,000 for the quarter ended December 31, 2020. The
decrease in net other expense is primarily due to a $23,000 decrease in interest
expense as a result of lower average borrowings on long-term debt. Net other
income for the six months ended December 31, 2021, was $875,000 compared to net
other expense of $100,000 for the six months ended December 31, 2020. The
increase in net other income is primarily due to a $943,000 employee retention
credit for funds received or receivable from the U.S. federal government under
the CARES Act.
Loss Before Income Tax
Pre-tax loss for the quarter ended December 31, 2021 was $1,441,000 compared to
$663,000 for the quarter ended December 31, 2020. The $768,000 increase in
pre-tax loss was attributable to a decrease of $1,260,000 in gross profit
partially offset by a decrease of $456,000 in SG&A and an decrease of $26,000 in
other expense. Pre-tax loss for the six months ended December 31, 2021 was
$959,000 compared to $1,041,000 for the six months ended December 31, 2020. The
$82,000 decrease in pre-tax loss was attributable to a decrease of $1,498,000 in
gross profit offset by a decrease of $605,000 in SG&A and an increase of
$975,000 in other income.
12
Table of Contents
Income Tax Provision
Income tax provision was $0 for the three and six months ended December 31, 2021
and $10,000 for the three and six months ended December 31, 2020, respectively.
See Liquidity and Capital Resources - Deferred Income Tax Assets below for more
information.
Net Loss
Net loss was $1,441,000 for the quarter ended December 31, 2021, compared to
$673,000 for the quarter ended December 31, 2020. Net loss was $959,000 for the
six months ended December 31, 2021, compared to $1,051,000 for the six months
ended December 31, 2020. The reasons for the changes in net loss are the same as
explained above under the heading Net Loss Before Income Tax.
Net Loss Attributable to Common Stockholders
Net loss attributable to common stockholders increased $717,000 to $1,623,000
for the quarter ended December 31, 2021, compared to $906,000 for the quarter
ended December 31, 2020. On a per share basis, net loss attributable to common
stockholders was $0.09 per share for the quarter ended December 31, 2021,
compared to $0.06 per share for the quarter ended December 31, 2020.
Net loss attributable to common stockholders decreased $150,000 to $1,328,000
for the six months ended December 31, 2021, compared to $1,478,000 for the six
months ended December 31, 2020. On a per share basis, net loss attributable to
common stockholders was $0.08 per share for the six months ended December 31,
2021, compared to $0.10 per share for the six months ended December 31, 2020.
Liquidity and Capital Resources
We have historically financed operations through cash from operating activities,
available cash reserves, borrowings under a line of credit facility (see Line of
Credit, below) and proceeds from the sale of our equity securities. As of
December 31, 2021, we had $3,573,000 in cash and cash equivalents and restricted
cash, compared to $6,254,000 as of June 30, 2021.
Working capital was $11,908,000 as of December 31, 2021, compared to working
capital of $12,433,000 as of June 30, 2021. The current ratio was 2.4 to 1 and
2.5 to 1 as of December 31, 2021 and June 30, 2021, respectively. Current assets
were 54.5% of total assets as of December 31, 2021, and 53.4% of total assets as
of June 30, 2021.
We believe that our cash generated from operations, current capital resources
and equity proceeds, and available credit provide sufficient liquidity to fund
operations for the next 12 months. However, the continuing effects of the
COVID-19 pandemic could have an adverse effect on our liquidity and cash and we
continue to evaluate and take action, as necessary, to preserve adequate
liquidity and ensure that our business can continue to operate during these
uncertain times.
In March 2020, we entered into an equity distribution agreement with Canaccord
Genuity LLC and Roth Capital Partners LLC, pursuant to which we arranged to
offer and sell shares of our common stock in an at-the-market offering ("ATM")
under a registration statement previously filed by us on Form S-3 with the
Securities and Exchange Commission. On March 13, 2020, we filed a Prospectus
Supplement amending the registration statement (as amended, the "Original
Registration Statement") and commenced the ATM. Under the terms of the equity
distribution agreement, we may sell shares of our common stock in an aggregate
amount of up to $10,000,000, with Canaccord Genuity LLC and Roth Capital
Partners LLC acting as our sales agents, at the market prices prevailing on The
Nasdaq Capital Market at the time of the sale of such shares. We will pay
Canaccord Genuity LLC and Roth Capital Partners, LLC a fixed commission rate
equal to 3.0% of the gross sale price per share of common stock sold. In May
2021, we filed a registration statement on Form S-3 together with a Prospectus
Supplement, for the purpose of replacing the Original Registration Statement,
which expired after three years, pursuant to applicable SEC rules. The
replacement registration statement provides for potential futures sales in
conjunction with a prospectus supplement for up to $2,677,997 in common stock in
the ATM.
13
Table of Contents
Cash and Cash Equivalents
Our cash and cash equivalents and restricted cash position decreased $2,681,000
to $3,573,000 as of December 31, 2021, compared to $6,254,000 as of June 30,
2021. The primary use of cash in the six months ended December 31, 2021, was for
inventories.
Accounts Receivable
Trade accounts receivable, net of allowance for doubtful accounts, decreased
approximately $51,000, or 0.9%, to $5,592,000 as of December 31, 2021, from
$5,643,000 as of June 30, 2021. The decrease was driven primarily by differences
in the timing of collections around the end date of each respective quarter.
Trade accounts receivable represents amounts due from our customers including
dealers and distributors that purchase our products for redistribution, medical
practitioners, clinics, hospitals, colleges, universities and sports teams. We
believe that our estimate of the allowance for doubtful accounts is adequate
based on our historical experience and relationships with our customers.
Accounts receivable are generally collected within approximately 40 days of
invoicing.
Inventories
Inventories, net of reserves, increased $2,798,000 or 42.9%, to $9,324,000 as of
December 31, 2021, compared to $6,526,000 as of June 30, 2021. The increase was
primarily due to steps taken to adjust inventory management in response to the
impact of COVID-19 on the global supply chain and right-size incoming material
purchases to demand. We believe that our allowance for inventory obsolescence is
adequate based on our analysis of inventory, sales trends, and historical
experience.
Accounts Payable
Accounts payable increased approximately $944,000 or 25.3%, to $4,682,000 as of
December 31, 2021, from $3,738,000 as of June 30, 2021. The increase was driven
primarily by an increase in inventory purchases and timing of payments.
Line of Credit
Our line of credit was $0 as of December 31, 2021 and June 30, 2021. On January
15, 2022, the expiration date, there were no outstanding borrowings on the Line
of Credit.
Debt
Long-term debt decreased approximately $7,000 to approximately $12,000 as of
December 31, 2021, compared to approximately $19,000 as of June 30, 2021. Our
long-term debt is primarily comprised of loans related to equipment.
Finance Lease Liability
Finance lease liability as of December 31, 2021 and June 30, 2021 totaled
approximately $2,431,000 and $2,596,000, respectively. Our finance lease
liability consists primarily of our Utah building lease. In conjunction with the
sale and leaseback of our Utah building in August 2014, we entered into a
15-year lease, classified as a finance lease, originally valued at $3,800,000.
The building lease asset is amortized on a straight-line basis over 15 years at
approximately $252,000 per year. Total accumulated amortization related to the
leased building is approximately $1,869,000 at December 31, 2021. The sale
generated a profit of $2,300,000, which is being recognized straight-line over
the life of the lease at approximately $150,000 per year as an offset to
amortization expense. The balance of the deferred gain as of December 31, 2021
is $1,153,000. Lease payments, currently approximately $31,000, are payable
monthly and increase annually by approximately 2% per year over the life of the
lease. Imputed interest for the three and six months ended December 31, 2021 was
approximately $33,000 and 67,000, respectively. In addition to the Utah
building, we have certain equipment leases that we have determined are finance
leases.
14
Table of Contents
Operating Lease Liability
Operating lease liability as of December 31, 2021 and June 30, 2021 totaled
approximately $2,028,000 and $2,470,000, respectively. Our operating lease
liability consists primarily of building leases for office, manufacturing, and
warehouse space.
Deferred Income Tax Assets
A valuation allowance is required when there is significant uncertainty as to
the realizability of deferred income tax assets. The ability to realize deferred
income tax assets is dependent upon our ability to generate sufficient taxable
income within the carryforward periods provided for in the tax law for each tax
jurisdiction. We have determined that we do not meet the "more likely than not"
threshold that deferred income tax assets will be realized. Accordingly, a
valuation allowance is required. Any reversal of the valuation allowance in
future periods will favorably impact our results of operations in the period of
reversal. As of December 31, 2021 and June 30, 2021, we recorded a full
valuation allowance against our net deferred income tax assets. This resulted in
no reported income tax expense associated with the operating profit reported
during the three and six months ended December 31, 2021.
Stock Repurchase Plans
We have a stock repurchase plan available to us at the discretion of the Board
of Directors. Approximately $449,000 remained of this authorization as of
December 31, 2021. No purchases have been made under this plan since September
2011.
Off-Balance Sheet Arrangements
As of December 31, 2021, we had no off-balance sheet arrangements.
Critical Accounting Policies
The preparation of our financial statements requires that we make estimates and
judgments. We base these on historical experience and on other assumptions that
we believe to be reasonable. Our critical accounting policies are discussed in
Item 7, "Management's Discussion and Analysis of Financial Condition and Results
of Operations" section of our Form 10-K for the year ended June 30, 2021. There
have been no material changes to the critical accounting policies previously
disclosed in that report.
15
Table of Contents© Edgar Online, source Glimpses
DYNATRONICS CORPORATION 
